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Acute Decompensated
Heart Failure: The Quest
to Live Longer and Feel Better
Can We Have it All?*
J. Malcolm O. Arnold, MD, Liane Porepa, MD
London, Ontario, Canada
Linus Pauling first popularized this quest in his famous
health book entitled How to Live Longer and Feel Better (1).
Although not a physician nor a heart failure specialist, he
identified 2 important endpoints in acute decompensated
heart failure (ADHF): reduce mortality (live longer) and
relieve dyspnea (feel better). Efforts to reduce mortality have
driven the design and primary endpoints of many clinical
trials, whereas symptom improvement is often a secondary
or lower endpoint (2). However, dyspnea relief remains an
important goal in ADHF (3,4).
See page 1441
ADHF is an important clinical syndrome affecting a
growing and aging population. It accounts for approxi-
mately 100,000 hospitalizations/year in Canada and 1 mil-
lion hospitalizations/year in the United States. In-hospital
mortality is high as are post-discharge readmission and
mortality rates. Patients in the ADHERE (Acute Decom-
pensated Heart Failure National Registry) had a 4% in-
hospital mortality, with a median length of stay of 4.3 days
(5). In the EuroHeart Failure survey I, 16.9% of patients
died on the index admission, 24.2% were readmitted within
12 weeks of discharge, and 13% died between admission and
12 weeks of follow-up (6). In the EuroHeart Failure survey
II, in-hospital mortality was 8.1% in de novo heart failure,
9.1% for those in pulmonary edema, and 30.6% in cardio-
genic shock (7). Randomized control trials inform the
strong evidence base for the treatment of most cardiovas-
cular conditions, but ADHF stands out because its man-
agement has previously been largely based on clinical expe-
rience and pathophysiological assumptions rather than
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chronic heart failure has evolved substantially, clinical trial
results in ADHF have been disappointing. Current medical
guidelines for ADHF are based largely on consensus inter-
ventions that provide symptom relief (2).
Why has it been challenging to demonstrate a mortality
benefit in ADHF therapies? The demographic and clini-
cal heterogeneity of the ADHF syndromes makes system-
atic evaluation challenging. None of the major ADHF trials
in the last decade have achieved a mortality benefit, though
improvements have been shown in other clinical outcomes
such as hemodynamic parameters, shorter hospital stay, and
dyspnea. Gaps in understanding the underlying pathophys-
iology of ADHF make it difficult to impact mortality with
single therapeutic agents over a short time frame. Discon-
nects exist between the focus on acute symptoms during
ADHF and the transition to chronic heart failure care,
though programs exist to try and bridge that continuum of
care.
Do we need to standardize our assessment of symptom
relief in ADHF? In light of the aforementioned chal-
lenges, a pragmatic approach would be to choose alternative
clinically meaningful endpoints to assess interventions in
ADHF. Is it sufficient to have a goal to make patients feel
better? Dyspnea would appear to be the most relevant and
important “feel better” outcome in ADHF and has recently
been emphasized as a treatment priority (4,8). Dyspnea has
been an endpoint (either coprimary or secondary) in the
majority of ADHF trials over the last decade, using tools
such the visual analogue (VA) or Likert scales. However,
dyspnea is subjective, dynamic, difficult to quantify, and not
amenable to blinding. Concerns over the lack of standard-
ization of dyspnea as an important clinical endpoint has led
to a consensus statement that “a standardized method with
which to assess dyspnea is required for clinical trials of acute
heart failure syndromes in order to ensure uniform collec-
tion of data on a key endpoint” (3). The criteria specified in
the document are for an instrument that is accurate, reliable,
and reproducible between and among observers.
In this issue of the Journal, Ezekowitz et al. (9) have
responded to this “call to action.” They report the results of
a substudy of the ASCEND-HF (Acute Study of Clinical
Effectiveness of Nesiritide in Decompensated Heart Fail-
ure) clinical trial that enrolled 421 patients admitted with
ADHF in whom peak expiratory flow rate (PEFR) was
measured at baseline and 1, 6, and 24 h after randomization
to nesiritide or placebo. The Dyspnea Index (DI) by Likert
scale was also collected at 6 and 24 h. The authors
hypothesized that PEFR would improve with ADHF treat-
ment over the first 24 h and would correlate with the DI
change and treatment effect. PEFR significantly increased at
each time interval, and the change was modestly correlated
to the DI. The concept of using pulmonary function testing
to measure response to congestive heart failure treatment is
not new. A 1983 study showed improved pulmonary func-
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(FEV1) and forced vital capacity in 28 patients admitted
with heart failure (10). A previous review paper suggested
serial measurement of lung function may be useful in
tracking pulmonary expression of disease or response to
therapy (11). An important component of the paper by
Ezekowitz et al. (9) was correlating the pulmonary function
test measure of PEFR with other previously validated
measures of dyspnea (Likert and VA scale). Furthermore,
linking dyspnea as a quantitative outcome to other impor-
tant clinical endpoints, such as the 30-day mortality and
heart failure re-hospitalization rates, was consistent with
suggested developments of dyspnea measurements (4).
PEFR, an effort-dependent measure of airflow limitation,
was chosen for its portability and strong evidence base in the
respiratory literature (12,13). In the cardiac literature, its utility
as a diagnostic tool to differentiate cardiac versus respiratory
dyspnea has been suggested in some smaller studies (14–16).
However, a number of questions arise. Can we assume
that the test characteristics, as validated in the pulmonary
population, are applicable to the heart failure population?
Should we question whether a measurement of airflow limita-
tion, determined mainly by large airway flow, is an oversim-
plification? The mechanism of dyspnea in ADHF is multifac-
torial and may be more complex than would be suggested by
this assessment tool. Nonetheless, in the absence of complete
physiological equanimity, a correlation was observed, and the
potential utility of PEFR as an objective reflection of improve-
ment in dyspnea was tested. Although its use as a diagnostic
tool for ADHF has not been widely used, PEFR may have
potential as a quantitative assessment tool for early response to
treatment as demonstrated in this study.
Are PEFR measurements ready for routine clinical use?
For PEFR to be validated as an assessment tool in the
ADHF population, more detailed information is needed.
How long was the time from first symptoms or first acute
medical intervention to first PEFR? Who specifically per-
formed the PEFR tests (physician, nurse, allied health)?
Was the patient allowed just 1 first attempt or multiple
attempts to determine how reproducible the measurements
were at each time interval? Was the patient in a standard
supine or upright position? The authors also concluded that
PEFR improved after nesiritide compared with placebo. How-
ever, the absolute difference of 7 liters in PEFR between
nesiritide and placebo, although numerically statistically signif-
icant, is below the minimal clinically important difference of
18 l/min in asthma and 10 to 32 l/min in chronic obstructive
pulmonary disease. Caution is also needed given the overall
ASCEND-HF trial did not show significant improvement in
dyspnea between nesiritide and placebo according to pre-
specified statistical parameters. Nesiritide also has a direct
bronchodilator effect, which begs the question as to whether
this result reflects a known property of nesiritide (17).
There are alternative objective measures of dyspnea that
could also be incorporated into future studies. The provoc-
ative dyspnea assessment scale is a threshold test that is feltto be more objective and sensitive to changes in dyspnea
compared with the Likert or VA scale (3). In patients with
milder symptoms, 47% had worsening dyspnea when placed
in the supine position versus sitting upright in the
URGENT-Dyspnoea study (Ularitide Global Evaluation in
Acute Decompensated Heart Failure) (8). Other pulmonary
function test components including FEV1, vital capacity, or
forced expiratory flow at 50%, could also be compared as
objective outcome measures in future studies (18,19). It
would be important to correlate PEFR measurements with
each of these measures, including additional clinical surro-
gates or hemodynamic parameters.
Should we pursue dyspnea as a standardized endpoint?
This is an important question to answer as it places the
impact of this research in perspective. Some may argue that
we already have interventions that provide dyspnea relief in
ADHF, and it is more important to improve “hard out-
comes.” The latter will require better pathophysiological
understanding of ADHF and the development of new
interventions. For patients, dyspnea remains a very impor-
tant goal of therapy. A more objective measure of dyspnea
improvement, such as PEFR, may facilitate assessment of
current and new drugs in the critical first hours and days,
and may help to identify drugs that have potential to
mprove some basic abnormalities in ADHF that might lead
o improved acute outcomes. This paper is the largest study
sing PEFR as an objective measurement of dyspnea in
DHF that both reflects clinical improvement and corre-
ates with the previously used dyspnea index. Although
any details will need to be further elucidated, it serves as
n excellent springboard for further study.
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